Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Had > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
Has a KOOS Pain of ≤ 75 (100 being the highest attainable and no pain)
Is between age 30 and 75 years (inclusive) at the time of study treatment
Has neutral alignment ± 5º of the mechanical axis, i.e., the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine to the center of the ankle joint
Has ≥ 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device AND is also recommended for the baseline non-surgical (and, if likely to receive benefit, any injection) therapies to be administered in the study.
Is willing to be entered into either arm of the study: implanted with the NUsurface device OR treated with the recommended control arm therapies.
Is able to do the study required follow up visits, questionnaires, X-rays, and MRI's
Is able and willing to understand and sign the study Informed Consent Form
Is able to read and understand the national language of the country in which the relevant clinical site is located

Exclusion Criteria:

Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy leaving > 4 mm of medial meniscus rim
Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a NUsurface implant (e.g., a focal lesion > 0.5 cm2 correlating to a circular defect of > 8 mm in diameter)
Has complete disruption of the posterior root attachment of the meniscus
Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral compartment
Has a varus or valgus knee deformity > 5º requiring a tibial or femoral osteotomy
Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the patellar compartment.
Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
Had an ACL reconstruction performed < 9 months prior to study treatment
Has a BMI > 32.5 at the start of study treatment
Decides to receive (if eligible and an option) allograft medial meniscus transplantation
Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the NUsurface® Meniscus Implant
Has a knee flexion contracture > 10º
Has flexion < 90º
Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO)
Has insufficiency fractures or avascular necrosis of the medial compartment
Has an active infection or tumor (local or systemic)
Has any type of knee joint inflammatory disease including Sjogren's syndrome
Has neuropathic knee osteoarthropathy, also known as Charcot joint
Has any medical condition that does not allow possible arthroscopy of the knee
Has neurological deficit (sensory, motor, or reflex)
Is currently involved in another investigation of the lower extremity
Anticipates having another lower extremity surgery during the study period
Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity [allergy] to hyaluronan [sodium hyaluoronate] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections
Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
Has received any corticosteroid knee injections ≤ 3 months prior to study treatment
Has chondrocalcinosis
Is on immunostimulating or immunosuppressing agents
Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
Is a female who is lactating, expecting, or is intending to become pregnant during the study period
Is an active smoker
Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
Is a prisoner
Is a patient who has economic incentive not to improve